David M. Nanus, MD, presented “Precision Diagnostics and Emerging Treatment Strategies” during the 7th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on September 22, 2023.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Nanus, David M. “Precision Diagnostics and Emerging Treatment Strategies.” September 22, 2023. Accessed Dec 2024. https://grandroundsinurology.com/precision-diagnostics-and-emerging-treatment-strategies/
Precision Diagnostics and Emerging Treatment Strategies – Summary
David M. Nanus, MD, Dr. David Nanus, MD, explores the advancements in diagnostic techniques and novel therapies that promise to revolutionize prostate cancer care. He addresses the limitations of traditional diagnostic methods and treatments, offering precision diagnostics as a solution, and highlighting technologies such as next-generation sequencing, liquid biopsies, and multi-parametric MRI. These tools enable detailed molecular and genetic profiling of prostate tumors, allowing for the identification of specific mutations and biomarkers that can guide targeted therapy.
Nanus outlines various novel therapies, including next-generation androgen receptor inhibitors, PARP inhibitors, and immunotherapies. He provides evidence that underscores the potential for precision medicine to improve outcomes in prostate cancer care.
The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a unique multi-disciplinary forum organized to inform the key health care stakeholders about the emerging advances in clinical case and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization. The mission of the Summit is to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of novel observation strategies (e.g., active surveillance, or AS) and therapeutic interventions.
ABOUT THE AUTHOR
David M. Nanus, MD, is the Mark W. Pasmantier Professor of Hematology and Medical Oncology in Medicine and the Director of Genitourinary Cancer at New York-Presbyterian Hospital – Weill Cornell Medicine Healthcare System Cancer Program. He is also Associate Director of Clinical Services at the Meyer Cancer Center at Weill Cornell.
Dr. Nanus completed his medical training at Albert Einstein College of Medicine in the Bronx. He then went on to complete a Fellowship in Medical Oncology at Memorial Sloan Kettering Cancer Center, and completed research training at the Sloan Kettering Institute in Manhattan. He was a physician-scientist at MSKCC and later joined the full-time faculty of Weill Cornell Medicine, where he serves as Chief of the Division of Hematology and Medical Oncology. He serves as PI in clinical, translational, and basic research in genitourinary malignancies and novel targeted therapies, and has 200+ publications. He has received numerous awards, including membership in the American Society for Clinical Investigation and the Association of American Physicians.
